Last reviewed · How we verify
TQ05105 Tablets
At a glance
| Generic name | TQ05105 Tablets |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects (PHASE1)
- A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) (PHASE1, PHASE2)
- A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis (PHASE2)
- A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets (PHASE1)
- A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) (PHASE1, PHASE2)
- A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD) (PHASE1, PHASE2)
- A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease (PHASE1, PHASE2)
- TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TQ05105 Tablets CI brief — competitive landscape report
- TQ05105 Tablets updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI